Sol-Gel Technologies SLGL
NASDAQ SLGL
$69.96 -0.14 (-0.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

Sol-Gel Technologies (SLGL) Non-Current Assets (2016 - 2026)

Sol-Gel Technologies (SLGL) posted quarterly Non-Current Assets of $2.8 million for Q1 2026, down 23.96% year-over-year from $3.6 million in Q1 2025, and down 6.28% quarter-over-quarter from $2.9 million in Q4 2025.

Analysis

Sol-Gel Technologies (SLGL) Non-Current Assets (2016 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Non-Current Assets for 11 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Non-Current Assets fell 23.96% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 23.96% YoY), while the FY2025 annual figure was $2.9 million, down 35.27% from the prior year.
  • Non-Current Assets slipped to $2.8 million in Q1 2026 per SLGL's latest filing, from $2.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $9.3 million in Q1 2022 and bottomed at $2.8 million in Q1 2026.
  • Historically, Non-Current Assets has averaged $4.5 million across 5 years, with a median of $3.7 million in 2022.
  • On a YoY basis, Non-Current Assets climbed as much as 75.06% in 2022 and fell as far as 70.43% in 2022.
  • Sol-Gel Technologies' Non-Current Assets stood at $3.6 million in 2022, then climbed by 15.31% to $4.1 million in 2023, then grew by 10.46% to $4.6 million in 2024, then sank by 35.27% to $2.9 million in 2025, then fell by 6.28% to $2.8 million in 2026.
  • Business Quant data shows SLGL's Non-Current Assets at $2.8 million in Q1 2026, $2.9 million in Q4 2025, and $2.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 14.88 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 23.28 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1.96 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 5.15 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 294.93 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1.96 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 938.60 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 18.06 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 468.65 Mn
10 Sol-Gel Technologies 194.01 Mn 146.08 Mn - 2.68 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.68 Mn
Mar 31, 2026 2.76 Mn
Dec 31, 2025 2.95 Mn
Sep 30, 2025 2.94 Mn
Jun 30, 2025 3.05 Mn
Mar 31, 2025 3.63 Mn
Dec 31, 2024 4.55 Mn
Sep 30, 2024 5.03 Mn
Jun 30, 2024 3.72 Mn
Mar 31, 2024 3.90 Mn
Dec 31, 2023 4.12 Mn
Sep 30, 2023 4.39 Mn
Jun 30, 2023 3.51 Mn
Mar 31, 2023 8.36 Mn
Dec 31, 2022 3.57 Mn
Sep 30, 2022 3.73 Mn
Jun 30, 2022 6.51 Mn
Mar 31, 2022 9.34 Mn
Dec 31, 2021 12.08 Mn
Sep 30, 2021 4.68 Mn